



# Clinical Cannabinoid Pharmacy 2020: Advanced Clinical Cannabinoid Considerations

## Learning Objectives:

*Upon successful completion of this knowledge-based course pharmacists should be able to:*

1. Explain the neuropsychiatric implications of Cannabis use in various populations
2. Evaluate the role of phytocannabinoids in various degenerative and non-degenerative neurological disorders
3. Outline the role of Cannabis medicine in gastrointestinal disorders
4. Evaluate the use of medical Cannabis in special populations including pregnancy and lactation, pediatrics, young adults, and geriatrics.
5. Identify the potential relationship between the ECS and various exploratory conditions
6. Design safe and effective palliative care regimens for special populations including pediatrics and geriatrics
7. Interpret the future of Cannabis medicine and the role of the healthcare professional

## Faculty:

### **Kareem M. Abdalla, PharmD**

Founder & Consultant  
CannaClarified

### **Laura Borgelt, PharmD, MBA, FCCP, BCPS**

Professor and Associate Dean of Administration and Operations  
University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy

### **Brian Essenter, RPh**

Dispensary Manager  
Affinity Health and Wellness

### **Bonni Goldstein, MD**

Medical Director  
Canna-Centers

### **Melani Kane, PharmD**



President/Executive Director  
ISCPH

**J. Cobb Scott, PhD**  
Professor  
University of Pennsylvania

**Dustin Sulak D.O.**  
Medical Director, Healer  
Zelira Therapeutics Ltd, COR Analytics

**Stacia Woodcock, PharmD**  
Dispensary Manager  
CuraLeaf

**Christine Roussel, PharmD, BCOP**  
Director of Pharmacy  
Doylestown Hospital

**Laszlo Mechtler, MD, FAAN, FEAN, FASN, FAHS**  
Medical Director  
Dent Neurological Institute

### **Faculty Disclosure:**

Dr. Abdalla reports that he is a consultant at CannaClarified.

Brian Essenter reports that he is an employee at Affinity Health and Wellness.

Dr. Goldstein reports that she is a consultant at WeedMaps.

Dr. Scott reports that he receives grant/research support from NIH and Department of Veterans Affairs.

Dr. Mechtler reports that he is a consultant at Jushi.



Dr. Woodcock reports that she is a dispensary manager at CuraLeaf.

Dr. Sulak reports that he is a consultant, Major stockholder and receives other financial/material support from Zelira Therapeutics Ltd, COR Analytics.

CEI has taken appropriate action for conflict resolution, including external peer review.

Dr. Borgelt, Dr. Kane, and Dr. Roussel do not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course.

#### CPE Credit



CEI is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

**UAN:** 0107-9999-20-234-L01-P | 0.60 CEUs/6.0 Hrs.

0107-9999-20-234-H01-P | 0.60 CEUs/6.0 Hrs.

Live Course Date: August 15<sup>th</sup>, 2020

Live Expiration Date: September 14<sup>th</sup>, 2020

On Demand Release Date: August 15<sup>th</sup>, 2020

On Demand Expiration Date: August 15<sup>th</sup>, 2021

*LIVE: To obtain 6.0 contact hours of continuing pharmacy education credit (0.6 CEU), participants must participate in the live course, and logon to the CEImpact website to complete the exam and evaluation. Once successfully completed, click Submit. The CPE Statement of Credit can then be accessed on CPE Monitor, [www.MyCPEMonitor.net](http://www.MyCPEMonitor.net).*

*ON DEMAND: To obtain 6.0 contact hours of continuing pharmacy education credit (0.6 CEU), participants must participate in the on-demand course, and complete the exam and evaluation. Once successfully completed, click Submit. The CPE Statement of Credit can then be accessed on CPE Monitor, [www.MyCPEMonitor.net](http://www.MyCPEMonitor.net).*



### **Course Format**

Live and on-demand.

### **Financial Support**

None.

### **Course Fee (includes 16 hours of CPE)**

Member \$399

Non-Member \$499

---